These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 33971856)

  • 1. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
    Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
    Albers FC; Papi A; Taillé C; Bratton DJ; Bradford ES; Yancey SW; Kwon N
    Respir Res; 2019 Jul; 20(1):169. PubMed ID: 31362741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
    Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
    Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
    Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
    Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
    Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.